Table 1 The baseline characteristics of training and validations sets
Clinical variables | Training set | Validation set | P-value |
|---|---|---|---|
Total | 480 | 206 | Â |
Sex (%) | Â | Â | 0.9976 |
 Male | 282 (58.8) | 121 (58.7) |  |
 Female | 198 (41.2) | 85 (41.3) |  |
Age (years) | Â | Â | Â |
 Median (IQR) | 59 (51–64) | 57.5 (50–64) | 0.2370 |
BRAF | Â | Â | 0.3389 |
 Wild type | 464 (96.7) | 196 (95.1) |  |
 Mutant type | 16 (3.3) | 10 (4.9) |  |
KRAS | Â | Â | 0.2605 |
 Wild type | 288 (60.0) | 133 (64.6) |  |
 Mutant type | 192 (40.0) | 73 (35.4) |  |
MLH1 | Â | Â | 0.9204 |
 Wild type | 444 (92.5) | 191 (92.7) |  |
 Mutant type | 36 (7.5) | 15 (7.3) |  |
MSH2 | Â | Â | 0.7817 |
 Wild type | 459 (95.6) | 196 (95.1) |  |
 Mutant type | 21 (4.4) | 10 (4.9) |  |
MSH6 | Â | Â | 0.9967 |
 Wild type | 452 (94.2) | 194 (94.2) |  |
 Mutant type | 28 (5.8) | 12 (5.8) |  |
PMS2 | Â | Â | 0.7898 |
 Wild type | 441 (91.9) | 188 (91.3) |  |
 Mutant type | 39 (8.1) | 18 (8.7) |  |
Tumor site | Â | Â | 0.8266 |
 Ascending colon | 96 (20.0) | 34 (16.5) |  |
 Transverse colon | 9 (1.9) | 4 (1.9) |  |
 Descending colon | 26 (5.4) | 12 (5.8) |  |
 Sigmoid colon | 89 (18.5) | 36 (17.5) |  |
 Rectum | 260 (54.1) | 120 (58.2) |  |
Diabetes | Â | Â | 0.3733 |
 No | 422 (87.9) | 176 (85.4) |  |
 Yes | 58 (12.1) | 30 (14.6) |  |
Hypertension | Â | Â | 0.4955 |
 No | 341 (71.0) | 141 (68.4) |  |
 Yes | 139 (29.0) | 65 (31.6) |  |
Aspirin medication history | Â | Â | 0.0450 |
 No | 438 (91.3) | 197 (95.6) |  |
 Yes | 42 (8.7) | 9 (4.4) |  |
CEA | Â | Â | 0.8270 |
 Median (IQR) | 3.53 (2.03-7.8875) | 3.475 (1.87-8.7225) |  |
CA-199 | Â | Â | 0.1690 |
 Median (IQR) | 13.01 (7.8975–23.585) | 15.23 (8.355-23.9375) |  |
CA-724 | Â | Â | 0.1510 |
 Median (IQR) | 1.2975 (2.64-5.6225) | 2 (1.115–5.0375) |  |
WBC | Â | Â | 0.5930 |
 Median (IQR) | 7.4 (5.82-10.1625) | 7.175 (5.6075–9.7325) |  |
Neutrophils | Â | Â | Â |
 Median (IQR) | 5 (3.6-8.1425) | 4.64 (3.5-7.6725) | 0.3320 |
Lymphocytes | Â | Â | 0.2110 |
 Median (IQR) | 1.4 (0.83–1.86) | 1.49 (0.96-1.9275) |  |
Platelets | Â | Â | 0.6530 |
 Median (IQR) | 234 (188–290) | 230 (187.25–288.5) |  |
PLR | Â | Â | 0.7390 |
 Median (IQR) | 48.35 (26.37–71.59) | 49.60 (30.89–68.86) |  |
NLR | Â | Â | 0.1790 |
 Median (IQR) | 0.31 (0.11–0.46) | 0.34 (0.15–0.49) |  |
Pathological type | Â | Â | 0.1113 |
 Adenocarcinoma | 372 (77.5) | 173 (84.0) |  |
 Mucinous adenocarcinoma | 107 (22.3) | 32 (15.5) |  |
 Signet ring cell carcinoma | 1 (0.2) | 1 (0.5) |  |
Degree of differentiation | Â | Â | 0.3128 |
 High differentiation | 1 (0.2) | 0 (0.0) |  |
 Medium differentiation | 348 (72.5) | 160 (77.7) |  |
 Low differentiation | 131 (27.3) | 46 (22.3) |  |
Infiltration depth | Â | Â | 0.7707 |
 1 | 13 (2.7) | 4 (1.9) |  |
 2 | 52 (10.8) | 25 (12.1) |  |
 3 | 118 (24.6) | 45 (21.8) |  |
 4 | 297 (61.9) | 132 (64.1) |  |
Vascular tumor thrombus | Â | Â | 0.4170 |
 No | 421 (87.7) | 176 (85.4) |  |
 Yes | 59 (12.3) | 30 (14.6) |  |
Nerve invasion | Â | Â | 0.6466 |
 No | 377 (78.5) | 165 (80.1) |  |
 Yes | 103 (21.5) | 41 (19.9) |  |
Lymph node metastasis | Â | Â | 0.9211 |
 No | 301 (62.7) | 130 (63.1) |  |
 Yes | 179 (37.3) | 76 (36.9) |  |
N stage | Â | Â | 0.9756 |
 0 | 301 (62.7) | 131 (63.6) |  |
 1 | 134 (27.9) | 56 (27.2) |  |
 2 | 45 (9.4) | 19 (9.2) |  |
Number of positive Lymph node | Â | Â | 0.9830 |
 Median (IQR) | 0 (0–1) | 0 (0–1) |  |
Metastasis | Â | Â | 0.4989 |
 No | 453 (94.3) | 197 (95.6) |  |
 Yes | 27 (5.6) | 9 (4.4) |  |
TNM stage | Â | Â | 0.9100 |
 1 | 51 (10.6) | 23 (11.2) |  |
 2 | 240 (50.0) | 102 (49.5) |  |
 3 | 162 (33.8) | 72 (35.0) |  |
 4 | 27 (5.6) | 9 (4.4) |  |
Macroscopic classification | Â | Â | 0.9249 |
 Ulcer | 432 (90.0) | 184 (87.6) |  |
 Infiltration | 3 (0.6) | 1 (0.4) |  |
 Bulge | 45 (9.4) | 21 (10.2) |  |
Tumor size (long diameter) | Â | Â | Â |
 Median (IQR) | 4.5 (3.5–5.5) | 4.35 (3.125-5) |  |
Chemotherapy | Â | Â | 0.4828 |
 No | 219 | 88 |  |
 Yes | 261 | 118 |  |